Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma

BACKGROUND: Molecularly targeted agents with anti-angiogenic activity, including bevacizumab, have demonstrated clinical activity in patients with advanced/metastatic hepatocellular carcinoma (HCC). This multicentre phase II study involving patients from several Asian countries sought to evaluate th...

Descripción completa

Detalles Bibliográficos
Autores principales: Hsu, C-H, Yang, T-S, Hsu, C, Toh, H C, Epstein, R J, Hsiao, L-T, Chen, P-J, Lin, Z-Z, Chao, T-Y, Cheng, A-L
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2010
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844032/
https://www.ncbi.nlm.nih.gov/pubmed/20160718
http://dx.doi.org/10.1038/sj.bjc.6605580

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2844032/
https://www.ncbi.nlm.nih.gov/pubmed/20160718
http://dx.doi.org/10.1038/sj.bjc.6605580

Ejemplares similares